[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.106.138. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 570
Citations 0
Research Letter
April 2016

FLT3 Inhibitor–Associated Neutrophilic Dermatoses

Author Affiliations
  • 1Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia
  • 2Department of Pathology, The University of Arizona College of Medicine, Tucson
  • 3Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia
  • 4Department of Dermatology and Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia
  • 5Division of Hematology and Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia
JAMA Dermatol. 2016;152(4):480-482. doi:10.1001/jamadermatol.2015.6121

Acute myeloid leukemia (AML) is a hematologic malignancy characterized by a disruption in normal hematopoiesis that results in uninhibited myeloblast proliferation. Cutaneous reactions in AML include leukemia cutis, Sweet syndrome, infections, and treatment-related effects. We present 3 cases of FLT3 (OMIM 136351) inhibitor–associated neutrophilic dermatoses (Table).

First Page Preview View Large
First page PDF preview
First page PDF preview
×